Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
Palabras clave :
Non-hodgkin diffuse large B-cell lymphoma
Follicular lymphoma
Rituximab
Safety
Administration-related reactions
Fecha de publicación :
2020
Nota:
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Cita:
Garcia-Muñoz, R. (R.); Quero, C. (C.); Pérez-Persona, E. (Ernesto); et al. "Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study". British journal of haematology. 188 (5), 2020, 661 - 673
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.